A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer · Phase III
SITE011 (ITA) · Dr. Jansen
consented 2022-09-28
Adverse events
Grade 1 Colitis — outcome: RECOVERED/RESOLVED; onset 2022-12-18 (study day 70); relationship: Y
Grade 2 Anaemia — outcome: RECOVERED/RESOLVED; onset 2022-12-25 (study day 77); relationship: not assessed
Grade 2 Nausea — outcome: RECOVERED/RESOLVED; onset 2023-01-18 (study day 101); relationship: not assessed
Grade 2 Vomiting — outcome: RECOVERED/RESOLVED; onset 2023-03-02 (study day 144); relationship: N
Grade 2 Vomiting — outcome: RECOVERED/RESOLVED; onset 2023-04-22 (study day 195); relationship: not assessed
Grade 1 Nausea — outcome: UNKNOWN; onset 2023-05-17 (study day 220); relationship: not assessed
Grade 1 Nausea — outcome: RECOVERED/RESOLVED; onset 2023-08-18 (study day 313); relationship: N
Grade 2 Vomiting — outcome: RECOVERED/RESOLVED; onset 2023-08-23 (study day 318); relationship: not assessed
Grade 2 Dyspnoea — outcome: RECOVERED/RESOLVED; onset 2024-03-15 (study day 523); relationship: not assessed
Grade 3 Nausea — outcome: RECOVERED/RESOLVED; onset 2024-06-22 (study day 622); relationship: not assessed
Data queries
No data queries.